A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says cutting-edge biotechnology leader, NuView Life Sciences. CEO Paul Crowe will present the findings to the Boston Oncology Investor Conference, outlining the steps in the successful study and addressing the technology’s future. …more…
Press Releases
Binding Cell Receptors Key to New Prostate Cancer Diagnostic Test from NuView Life Sciences
Recent Posts
- NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
- Targeting VPAC1 Receptors for Imaging Glioblastoma
- NuView Life Sciences Creates Subsidiary for Latin American Market
- Jay Bishoff, MD, joins The Smith Institute for Urology
- Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics
Archives
- October 2022
- January 2022
- November 2021
- August 2021
- February 2021
- January 2021
- November 2020
- August 2020
- June 2020
- May 2020
- October 2019
- September 2019
- August 2019
- July 2019
- April 2019
- March 2019
- January 2019
- November 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- March 2013
- February 2013
- February 2000
- January 2000
Recommended For You
NewsPress Releases
NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
Karla Jo HelmsOctober 5, 2022
Press Releases
NuView Life Sciences Creates Subsidiary for Latin American Market
NVLSNovember 17, 2021
Press Releases
Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses
Karla Jo HelmsFebruary 8, 2021